BDRX — Biodexa Pharmaceuticals Plc

Summary of BDRX Q2 2021 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: The company reported an increase in revenues attributed to collaboration partnerships, particularly in the Q-Sphera programs.
• Cost Management: R&D expenses were approximately £2 million, and administrative costs were £1.6 million, leading to a total net loss of just over £3 million for the half-year, reflecting a burn rate of about £0.5 million per month.
• Balance Sheet: Cash on hand was £4.5 million at the half-year mark, but following a £9 million raise in July, the current cash position is closer to £12 million, providing a runway into Q1 2023.
• Debt: All Spanish loans have been repaid, and the balance sheet has been cleaned up.

2. Strategic Updates and Business Highlights

• Pipeline Progress: Key programs such as brexpiprazole and tacrolimus have moved from formulation to preclinical stages. MTX110 is advancing with the DIPG program moving to Phase II and GBM to Phase I trials.
• Q-Sphera Technology: The company has successfully demonstrated the ability to encapsulate proteins without denaturation, which is crucial for developing long-acting formulations.
• Partnerships: Collaborations are ongoing with partners for programs 213, 214, and 216, with proof-of-concept formulations delivered and in vivo studies underway.
• Market Focus: The company is prioritizing the GBM market due to its larger patient population and market potential, while also refining the DIPG program based on FDA feedback.

3. Forward Guidance and Outlook

• Cash Runway: The current cash position supports operations into Q1 2023, with no significant licensing fees expected from third parties in the short term.
• Market Potential: The GBM market represents a significant opportunity, estimated at $3 to $5 billion, and the company aims to leverage its unique delivery system to penetrate this market effectively.

4. Bad News, Challenges, or Points of Concern

• DIPG Program Response: There has been disappointment regarding the lack of market interest in the DIPG data, despite promising survival rates.
• Partnership Termination: The termination of the partnership with Dr. Reddy's was noted as disappointing, attributed to the unsuitability of their molecules for Q-Sphera technology.
• Technical Challenges: Ongoing technical hurdles include developing a reliable dissolution assay for the Q-Sphera formulations and ensuring injectability without causing patient discomfort.

5. Notable Q&A Insights

• Technical Challenges: Stephen Stamp highlighted the successful encapsulation of proteins and the need to further improve drug loading and dissolution measurement techniques.
• Market Strategy: There is a strategic desire to maintain a balanced portfolio of internal and partnered programs to mitigate risks associated with reliance on a single partner.
• Shareholder Engagement: The management is actively engaging with investors through roadshows and research publications to boost interest in the stock, despite current share price challenges.

Overall, while Midatech Pharma has made significant strides in its pipeline and financial management, it faces challenges in market perception and technical execution that need to be addressed moving forward.